Morphine intoxication by morphine-6-glucuronide, a pharmacologically active morphine metabolite, in chronic renal failure

被引:11
作者
Dubs, A [1 ]
Wiedemeier, P [1 ]
Caduff, B [1 ]
机构
[1] Spital Limmattal, Med Klin, CH-8952 Schlieren, Switzerland
关键词
D O I
10.1055/s-2007-1024449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
History and admission findings:A 57-year-old woman with metastasizing ovarian cancer and chronic renal failure was admitted for morphine treatment of an acute lumbospinal pain syndrome, ambulant treatment with analgesics having failed provide adequate pain relief. On admission due to pain the concious patient presented with reduced general condition and lumbal pain sensitive to tapping. Lasegue's sign was positive on both sides, no other disturbed neurological functions were found. Treatment and course: On the 7(th) day of morphine administration she became somnolent and breathing became markedly depressed, indicating overdosage, metabolic and intracranial causes having been excluded. Naloxone, an opioid antagonist, was given i.v. and the:breathing pattern improved. But drowsiness continued for another 48 hours and only regressed after repeated doses of naloxone. Conclusions: Morphine-6-glucuronide (M6G), formed from morphine in the liver, accumulates in blood and penetrates the blood-brain barrier, binding with strong affinity to opiate receptors and exerts a strong analgesic effect. As M6G is excreted by the kidney, its concentration rises in renal failure and can lead to severe intoxication. Morphine dosage must therefore be carefully controlled in patients with renal failure.
引用
收藏
页码:896 / 898
页数:3
相关论文
共 18 条
[1]   MORPHINE-6-GLUCURONIDE MIGHT MEDIATE THE PROLONGED OPIOID EFFECT OF MORPHINE IN ACUTE-RENAL-FAILURE [J].
BODD, E ;
JACOBSEN, D ;
LUND, E ;
RIPEL, A ;
MORLAND, J ;
WIIKLARSEN, E .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1990, 9 (05) :317-321
[2]   THE USE OF SEDATIVE AGENTS IN CRITICALLY ILL PATIENTS [J].
BURNS, AM ;
SHELLY, MP ;
PARK, GR .
DRUGS, 1992, 43 (04) :507-515
[3]   Pharmacokinetics of opioids in renal dysfunction [J].
Davies, G ;
Kingswood, C ;
Street, M .
CLINICAL PHARMACOKINETICS, 1996, 31 (06) :410-422
[4]   OPIOID ROTATION FOR TOXICITY REDUCTION IN TERMINAL CANCER-PATIENTS [J].
DESTOUTZ, ND ;
BRUERA, E ;
SUAREZALMAZOR, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (05) :378-384
[5]   Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain [J].
Faura, CC ;
Moore, RA ;
Horga, JF ;
Hand, CW ;
McQuay, HJ .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1996, 11 (02) :95-102
[6]   MORPHINE PHARMACOKINETICS AND METABOLISM IN HUMANS - ENTEROHEPATIC CYCLING AND RELATIVE CONTRIBUTION OF METABOLITES TO ACTIVE OPIOID CONCENTRATIONS [J].
HASSELSTROM, J ;
SAWE, J .
CLINICAL PHARMACOKINETICS, 1993, 24 (04) :344-354
[7]   EXPLANATION AT THE OPIOID RECEPTOR LEVEL FOR DIFFERING TOXICITY OF MORPHINE AND MORPHINE 6-GLUCURONIDE [J].
HUCKS, D ;
THOMPSON, PI ;
MCLOUGHLIN, L ;
JOEL, SP ;
PATEL, N ;
GROSSMAN, A ;
REES, LH ;
SLEVIN, ML .
BRITISH JOURNAL OF CANCER, 1992, 65 (01) :122-126
[8]  
LEHMANN KA, 1993, EUR J PAIN, V14, P28
[9]   ORAL MORPHINE IN CANCER PAIN - INFLUENCES ON MORPHINE AND METABOLITE CONCENTRATION [J].
MCQUAY, HJ ;
CARROLL, D ;
FAURA, CC ;
GAVAGHAN, DJ ;
HAND, CW ;
MOORE, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) :236-244
[10]   THE INFLUENCE OF RENAL-FUNCTION ON THE RENAL CLEARANCE OF MORPHINE AND ITS GLUCURONIDE METABOLITES IN INTENSIVE-CARE PATIENTS [J].
MILNE, RW ;
NATION, RL ;
SOMOGYI, AA ;
BOCHNER, F ;
GRIGGS, WM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (01) :53-59